| Revenue growth | FY26 revenue grew 16.6% YoY; International led with 22.2% growth. |
|---|---|
| Margins | EBITDA margins improved 80bps to 19.4% in FY26; FY27 expansion target. |
| Order book | Strong ARV order book; sustained growth in non-ARV emerging markets. |
| Demand visibility | Strong demand in Chronic, Women's Health, and International niche segments. |
| Management confidence | High confidence in R&D and international scale-up; Zuventus recovery planned. |
Growth
FY26 revenue grew 16.6% YoY to ₹9,204cr; international markets jumped 22.2% while domestic grew 10%.
Outlook
Guided low-to-mid teens revenue growth for FY27 with 75-100bps EBITDA margin expansion target.
Risks
Near-term domestic underperformance due to Zuventus restructuring and higher field force attrition; volatile raw material costs.
Earnings Call filed with BSE, NSE: EMCURE. Summary written with AI assistance from the document.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,905.90
- Market cap
- ₹36,157 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 35.8×Sector 47.4×
- Promoter holding
- 77.83%-0.04% QoQ
- FII holding
- 4.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals Credit Rating
Emcure Pharmaceuticals received a credit rating reaffirmation from CARE Ratings for its existing bank facilities. The company maintains its stable outlook and financial profile.
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as part of its Annual Report.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals has issued a notice for its 45th Annual General Meeting to be held on September 21, 2026. The meeting will address financial statements, dividends, and directorship appointments.